In March of 2021, Puff Bar re-entered the US vape market with its disposable e-cigarettes, claiming that since their products contain synthetic nicotine instead of tobacco-derived nicotine, they fall outside of FDA’s regulatory authority. Many other companies have followed suit, and synthetic nicotine products are rising in popularity while FDA’s Center for Tobacco Products (CTP) attempts to rein in the market for tobacco-derived nicotine products. The webinar will begin with a scientific review of synthetic nicotine, including how it is made, how testing can distinguish it from tobacco-derived nicotine, and whether it poses its own unique health concerns. Following that review, the webinar will discuss perspectives on FDA’s authority to regulate these products and consider potential regulatory approaches at the federal, state, and local levels.
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Kevin Burd, Chief Executive Officer, Chemular, Inc. and Chief Executive Officer, North American Nicotine
Bonnie Coffa, Business Development Manager, Enthalpy Analytical
Kathleen Hoke, Law School Professor and Director, Network for Public Health Law Eastern Region, Francis King Carey School of Law, University of Maryland
Eric N. Lindblom, Independent Consultant and Senior Scholar, O’Neill Institute, Georgetown Law Center
Moderated by Kenneth Michael Cummings, Professor, Medical University of South Carolina
Virtual Learning FAQ